Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. TMU Publications / 北醫出版品
  3. .教師升等新聘著作
  4. 101學年度
  5. 張懷嘉教師資格審查資料
 
  • Details
Options

張懷嘉教師資格審查資料

Type
report
Date Issued
2011
Author(s)
張懷嘉
Subjects
類別:升等
送審等級:副教授
Description
101-1升等
教師升等著作
聘任單位:醫學系麻醉學科
送審等級:副教授
審查性質:專門著作-學術
代表著作:Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells
條碼號:C0218531
URI
https://203.71.86.71/handle/123456789/63952
File(s)
No Thumbnail Available
Name

C0218531.pdf

Size

21.26 MB

Format

Adobe PDF

Checksum

(MD5):05df76b4e2b5b40c1eba4c6c8e81f831

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback